ADAM21

Across TCGA pan-cancer cohorts, ADAM21 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated ADAM21 data layer compared with 7 for mutation status.

The strongest signal is observed in mesothelioma (MESO), where higher ADAM21 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ADAM21 expression acts as an unfavorable survival marker, although some lineages such as ESCA and KIRC show a favorable association.

MESO, CESC, and STAD are the cancer types where ADAM21 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Quartile	All	0.346	0.662	<.001	71	view →
CESC	DFS	Tertile	III,IV	0.239	0.769	.002	70	view →
STAD	DFS	Median	All	0.301	0.509	.011	59	view →
COAD	OS	Median	III,IV	0.664	0.891	.002	37	view →
LUAD	OS	Quartile	All	0.222	0.439	.002	27	view →
KICH	DFS	Median	III,IV	0.344	0.858	.010	21	view →
ESCA	DFS	Tertile	All	0.870	0.295	.004	20	view →
KIRP	DFS	Quartile	III,IV	0.451	0.844	.007	18	view →
UCEC	DFS	Quartile	All	0.763	0.865	.009	14	view →
KIRC	DFS	Tertile	All	0.843	0.706	.012	14	view →
THCA	DFS	Tertile	II,III,IV	0.949	0.609	.005	13	view →
READ	DFS	Quartile	III,IV	0.261	0.792	.008	13	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

ADAM21–MESO (OS)

Open the MESO breakdown →